It has been discovered that sleeping pills lower levels of Alzheimer's proteins.

Published Date: 26 Apr 2023

Sleep issues may be a precursor to Alzheimer's disease. Many people who are eventually diagnosed with Alzheimer's have trouble falling and staying asleep years before they develop cognitive issues like memory loss.

Read Full News

Latest News

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Todays Updates

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy Marco Meglio

A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic Isabella Ciccone, MPH

Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

Todays Updates

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy Marco Meglio

A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic Isabella Ciccone, MPH

Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

Latest News

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

News All Time

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug Marco Meglio

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

Incorporation of Mini-Mental State Exam Z-Scores May Increase Eligibility for Anti-Amyloid Treatments, Study Suggests Marco Meglio

A Korean study reveals that adjusted MMSE thresholds significantly increase eligibility for anti-amyloid treatments, highlighting demographic disparities and safety concerns.

Expanding Neurology Care in South Miami: Peter Abdelmalik’s Vision Marco Meglio, Peter Abdelmalik, MD

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Recommended News For You

Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia

The FDA Approves the New Frontline Aggressive ALL Regimen.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Hypnotherapy may offer real benefits for cancer patient care

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

Oncology Drug Shortages Persist, but Continue to Evolve

Recommended Articles For You

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

The Importance of Maintaining Normal Calcium Levels in Your Body  

Understanding Axitinib: What You Need To Know For Your Treatment Plan 

Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recently released national data on drug use and abuse among Americans.

2.

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

3.

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

4.

Scholastic performance is a key concern for young cancer patients, study finds

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

1.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

2.

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology

3.

Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances

4.

A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy

5.

Clinical Analysis of Prostate Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Navigating the Complexities of Ph Negative ALL - Part XI

5.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot